Why carryover matters
A peptide detected in an LC–MS run does not always originate entirely from the vial currently in the autosampler. A small amount of material from a previous injection can remain in the flow path and appear again in a later run. This residual signal is called carryover.
Carryover can be especially misleading when a high-response sample is followed by a low-response sample or a blank. It can inflate a measured response, create an apparent detection where no analyte was introduced, distort comparisons among samples, and make a method appear less precise than it is.
The solution is not simply to insert random blank injections. Laboratories need blanks with defined purposes, a sequence designed to reveal memory effects, and a troubleshooting plan that can distinguish carryover from contamination, interference, or a true sample signal.
This article is limited to laboratory analytical practice. It does not address personal use, clinical decisions, or health outcomes.
Carryover and contamination are related but not identical
The ICH M10 guideline defines carryover as an altered measured concentration caused by residual analyte from a preceding sample remaining in the analytical instrument.[1] The defining feature is sequence dependence: the signal in one run is influenced by what entered the system earlier.
Contamination is broader. It may be introduced during sample preparation, from shared tools, reagents, laboratory surfaces, airborne material, mislabeled containers, or instrument components. Contamination does not always follow the immediately preceding injection.
These distinctions matter because the corrective action depends on the source:
- A peak that appears only after a high-response injection suggests analytical carryover.
- A peak present in multiple process blanks may point to preparation-stage contamination.
- A background signal that persists regardless of injection order may come from reagents, the LC–MS source, or another recurring source.
- A peak at a different retention time or with inconsistent ion evidence may be an interference rather than residual analyte.
The first task is therefore to establish a pattern, not merely to note that an unexpected peak exists.
Where peptide carryover can occur
Any surface contacted by the sample can retain material. Potential locations include:
- pipette tips and preparation containers;
- autosampler vial inserts and caps;
- the sampling needle and needle seat;
- the injection loop, valve, rotor seal, and connecting tubing;
- trap or guard columns;
- the analytical column; and
- the ion source or transfer region of the mass spectrometer.
Peptides do not all interact with these surfaces in the same way. Sequence, size, charge, hydrophobicity, concentration, solvent composition, surface material, and chromatographic conditions can change adsorption and release behavior. A wash that works for one peptide may be insufficient for another.
Primary studies illustrate this method dependence. Dolman and colleagues compared peptide carryover across packed and monolithic capillary columns and observed large differences among column formats, with some reversed-phase packed columns retaining substantially more peptide signal than others.[2] In another study, Zhang and colleagues evaluated multiple peptides across containers, vial materials, stationary phases, gradients, flow rates, temperatures, and needle-wash conditions. The most effective combination depended partly on the peptide, and no single simple molecular descriptor explained all adsorption behavior.[3]
These results support a practical principle: carryover controls should be established with the actual analytical system and representative peptide materials, not assumed from a generic instrument setting.
A blank is only useful when its purpose is defined
Laboratories often use the word “blank” as though every blank answers the same question. It does not. Several blank types may be useful, and each isolates a different part of the workflow.
Solvent or reagent blank
A solvent blank contains the injection solvent or relevant reagent mixture without the target peptide. Injected after a high-response sample, it can reveal residual signal within the injection and chromatographic pathway. It does not test contamination introduced during the full sample-preparation process.
Matrix blank
A matrix blank contains the same background matrix used for samples but no intentionally added target analyte. It can help assess selectivity, endogenous background, matrix-related interference, and contamination associated with the matrix. For naturally occurring analytes, a genuinely analyte-free matrix may not be available, so the design must be justified carefully.
Process blank
A process blank passes through the preparation workflow without the target material. It can reveal contamination introduced by tubes, tips, reagents, extraction steps, work surfaces, or shared equipment. Because it includes more of the workflow, it answers a broader question than a solvent-only blank.
Carryover blank
A carryover blank is deliberately placed after a high-response sample or the highest calibration standard. Its location in the sequence is part of its definition. The objective is to determine whether the preceding injection affects the next result.
No-injection or bypass check
Some investigations use a gradient run without an autosampler injection, a direct pump flow check, or a temporarily modified flow path. These are troubleshooting experiments rather than routine blanks. They can help separate source contamination from autosampler, tubing, valve, or column contributions.
Naming the blank type in the method and run record prevents a common interpretation error: treating a clean solvent blank as proof that sample preparation was contamination-free, or treating a clean process blank as proof that the instrument cannot carry over material from a high injection.
Injection order determines what the sequence can reveal
A sequence should be designed so that carryover has an opportunity to show itself. If all low-response samples are injected before high-response samples, the run may never challenge the system in the direction most likely to create a false elevation.
ICH M10 directs laboratories to assess carryover during validation by analyzing blank samples after the highest calibration standard.[1] It also notes that, if carryover cannot be avoided, specific measures should be validated so residual signal does not affect analytical accuracy and precision. The FDA’s 2018 bioanalytical guidance similarly states that carryover should be eliminated during method development when possible and its effect assessed during validation when it cannot be eliminated.[4]
These documents apply formally to regulated bioanalytical work. In research laboratories, the same sequence logic remains useful: place blanks where they test a defined risk.
A purposeful sequence may include:
- an initial blank to assess background before sample exposure;
- system-suitability or conditioning injections;
- calibration and control materials, if the method is quantitative;
- a high-response challenge sample;
- one or more immediately following blanks;
- representative low-response samples; and
- periodic blanks or controls when a long sequence could accumulate contamination or drift.
Randomization remains valuable for reducing order bias, but it should not erase the ability to detect known sequence-dependent risks. If high samples can contaminate the next position, the laboratory must account for that risk in the sequence design.
Measuring carryover requires a predefined calculation and limit
A common calculation compares the analyte response in the blank after a high sample with the response at a defined low level. Another approach reports the blank signal as a percentage of the preceding high-response sample. These calculations answer different questions and should not be substituted without explanation.
ICH M10 provides a regulated bioanalytical benchmark: following the highest calibration standard, blank response should not exceed 20% of the analyte response at the lower limit of quantification and 5% of the internal-standard response.[1] Those values are not universal acceptance limits for every peptide research method. A laboratory should establish criteria that match the method’s intended purpose, sensitivity, dynamic range, and consequences of residual signal.
The procedure should define:
- which blank is used;
- where it appears in the sequence;
- which signal is measured;
- how the response is integrated;
- the denominator used in the calculation;
- the acceptance criterion;
- whether more than one blank is evaluated; and
- the required action when the criterion is exceeded.
A pass/fail label without this context is difficult to interpret or reproduce.
Why repeated blanks do not always solve the problem
Repeated blank injections may reduce residual signal, but they can also consume instrument time without identifying the retaining surface. A sequence of diminishing blank peaks confirms a memory effect; it does not automatically reveal whether the material is held by the needle, valve, tubing, guard column, analytical column, or source.
Yamagaki and Yamazaki systematically investigated neuropeptide Y carryover by changing or bypassing candidate parts of an LC–MS pathway. They identified contributions from the column—especially the guard column—as well as consumable seals associated with the sampling needle and high-pressure valve.[5] Replacing worn seals and separating system components during testing helped localize the problem.
That study demonstrates why a structured investigation is more informative than adding unlimited wash runs. The goal is to identify the source and control it, not merely to wait until the signal falls below the detection threshold.
A stepwise troubleshooting framework
When a carryover blank fails, laboratories can investigate from the simplest confirmation toward component-level isolation.
1. Confirm that the unexpected signal matches the analyte
Review retention time, accurate mass, isotope pattern, selected transitions or fragments, peak shape, and integration. A signal at the wrong retention time or with inconsistent ion evidence may be interference rather than carryover.
2. Examine the sequence pattern
Determine whether the signal appears specifically after high-response samples and whether it declines across successive blanks. Review the preceding injections, not just the failed blank.
3. Separate preparation contamination from instrument memory
Compare solvent blanks, process blanks, and matrix blanks. If the target appears in process blanks that were never injected after a high sample, preparation-stage contamination becomes more plausible.
4. Test the autosampler and injection path
Evaluate the needle, needle seat, loop, valve, rotor seal, and associated wash program. Worn consumables and inaccessible contact surfaces can retain material even when the visible needle is rinsed.
5. Evaluate the guard and analytical columns
Compare blanks with and without the column when the instrument configuration and laboratory procedure permit it. Review whether retention worsened after a column or guard-column change. A different stationary phase or column format may change the carryover profile even when the nominal chemistry appears similar.[2]
6. Evaluate the source and transfer region
If signal persists during checks that bypass the chromatographic injection pathway, inspect the ion source and transfer components according to the instrument manufacturer’s procedures.
7. Optimize and document the corrective action
Possible method changes include compatible needle-wash composition, wash volume or cycle count, gradient wash design, valve cleaning, consumable replacement, column cleaning, column replacement, or additional blank placement. Any change should be evaluated with representative materials and documented before routine use.
Solvents, wash conditions, and cleaning procedures must remain compatible with the instrument, seals, tubing, column, detector, and intended analytical method. A stronger wash is not automatically a safer or more effective wash.
What a defensible carryover record should contain
For each carryover assessment, record enough detail to reconstruct the challenge:
- instrument and method version;
- column and guard-column identifiers;
- autosampler wash settings;
- blank type and composition;
- identity and response of the preceding sample;
- sequence positions;
- analyte and internal-standard responses;
- calculation and acceptance limit;
- result and disposition;
- corrective action, if any; and
- confirmation that the correction was effective.
Trend review can add information that a single pass/fail result misses. Gradually increasing blank response may indicate developing contamination, column retention, or a worn component before the method fails its formal limit.
Where COA documentation fits
A lot-specific certificate of analysis helps researchers connect a material to reported testing for a particular batch. It does not establish that a receiving laboratory’s autosampler, column, wash program, or sequence is free from carryover.
Researchers should first match the vial and lot to the applicable documentation, then control carryover within their own analytical workflow. Bluegrass Research Lab’s COA directory provides available batch documentation. The Research Peptide Labels: Match Product, Size, and Lot to the COA article explains lot matching, while HPLC and Mass Spectrometry in Peptide Analysis provides background on what each analytical technique contributes.
The Bluegrass research catalog lists current research materials and links to applicable documentation. A product listing or COA should not be interpreted as proof that a separate laboratory’s analytical sequence has controlled carryover.
Laboratory checklist
Before relying on a peptide LC–MS sequence, confirm that:
- every blank type has a defined purpose;
- a blank follows a representative high-response challenge;
- the carryover calculation and acceptance criterion are written in advance;
- the method identifies the needle, valve, tubing, guard column, analytical column, and source as possible retention sites;
- process blanks distinguish preparation contamination from instrument memory;
- integration rules are consistent between samples and blanks;
- wash settings are compatible with the complete system;
- failed blanks trigger a documented investigation; and
- corrective actions are verified with representative material before routine use resumes.
Key takeaway
Carryover is a sequence-dependent analytical effect: material from an earlier injection contributes signal to a later run. Because residual peptide can remain at several points in an LC–MS pathway, one clean blank cannot prove that the entire workflow is controlled.
Reliable data require purposeful blank types, strategically placed carryover challenges, predefined calculations and limits, consistent integration, and a stepwise investigation when residual signal appears. The objective is not merely to make an unexpected peak disappear. It is to understand where it came from and demonstrate that the analytical procedure prevents it from changing the interpretation of subsequent samples.